Results 1 to 10 of about 570 (86)

Discovery of the anti-angiogenesis effect of eltrombopag in breast cancer through targeting of HuR protein

Acta Pharmaceutica Sinica B, 2020
HuR (human antigen R), an mRNA-binding protein responsible for poor prognosis in nearly all kinds of malignancies, is a potential anti-tumor target for drug development.
Yuying Zhu, Jiange Zhang, Ruixiang Li
exaly   +3 more sources

Development and Validation of Eltrombopag Determination in Human Plasma Blood by HPLC-MS Method

Разработка и регистрация лекарственных средств, 2022
Introduction. "Eltrombopag" is a thrombopoietin receptor agonist (TPO-RA) that is approved for the treatment of immune thrombocytopenic purpura (ITP).
А. М. AL-Dhuraibi, A. L. Kulikov, M. V. Pokrovskiy   +2 more
doaj   +1 more source

Elucidation of DNA-Eltrombopag Binding: Electrochemical, Spectroscopic and Molecular Docking Techniques

Biosensors, 2023
Eltrombopag is a powerful adjuvant anticancer drug used in treating MS (myelodysplastic syndrome) and AML (acute myeloid leukemia) diseases. In this study, the interaction mechanism between eltrombopag and DNA was studied by voltammetry, spectroscopic ...
Somaye Cheraghi, Pelin Şenel, Burcu Dogan Topal, Soykan Agar, Mahsa Majidian, Mine Yurtsever, Esen Bellur Atici, Ayşegül Gölcü, Sibel A. Ozkan   +8 more
doaj   +1 more source

Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain [PDF]

Farmacia Hospitalaria, 2020
Objective: Splenectomy, thrombopoietin receptor agonists and rituximab are the second-line treatments for steroid-resistant adult primary immune thrombocytopenia.
Eduardo Anguita, Francisco Javier Parrondo García, José Ramón González-Porras   +2 more
doaj   +1 more source

Current status and cost burden of non-first-line treatment in ITP: A multicenter study based on real-world data in China

Intelligent Pharmacy, 2023
Background: Eltrombopag, the first TPO-RA approved for the treatment of ITP, resulted in rapid and sustained increases in platelet counts, significant reductions in bleeding events and concomitant medications, and an acceptable tolerability profile. This
Lizong Li, Wenpei Wang, Xuecai Xue, Wenjuan Miao, Xiaofan Liu, Xiaoling Cheng, Xiaoling Wang, Lin Huang, Yufei Feng   +8 more
doaj   +1 more source

Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag?

Turkish Journal of Hematology, 2022
Objective: Eltrombopag remains a prominent option in the treatment of steroid-dependent or steroid-refractory immune thrombocytopenia (ITP) patients. Unfortunately, not all patients respond to eltrombopag.
Mehmet Baysal, Volkan Baş, Elif Ümit, Hakkı Onur Kırkızlar, Ahmet Muzaffer Demir   +4 more
doaj   +1 more source

Experience of off-label use of Eltrombopag in the treatment of thrombocytopenia associated with solid tumors [PDF]

Farmacia Hospitalaria, 2015
Purpose: To describe the results of the off-label use of eltrombopag in patients with solid tumors and thrombocytopenia that limits chemotherapy. Methods: Retrospective observational study including all patients with solid tumors who were treated with
María Henar García Lagunar, Pablo Cerezuela Fuentes, Mónica Martínez Penella, Dolores Paula Gutiérrez-Meca Maestre, María García Coronel, María José Martínez Ortiz   +5 more
doaj   +1 more source

The Efficacy of Eltrombopag Treatment in Patients who developed Platelet Engraftment Failure after Allogeneic Stem Cell Transplantation: A Single Center Experience

Bezmiâlem Science, 2021
Objective:Persistent thrombocytopenia is a common complication of allogeneic stem cell transplantation (ASCT). Treatment of platelet engraftment failure after ASCT remains controversial. Drugs, such as eltrombopag, are used for this purpose.
Ali ESER, Ayşen TİMURAĞAOĞLU
doaj   +1 more source

Clinical Care Team’s Guide for Awareness on Risk Assessment of Eltrombopag Complicating Acute Kidney Injury in Relapsed Immune Thrombocytopenic Patients: A Case Report

Medicina, 2023
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder caused by antigen-specific T cells and antiplatelet autoantibodies that inhibit platelet production in the bone marrow or destroy platelets in the spleen.
Eman Mostafa Hamed, Mohamed Hussein Meabed, Ahmed R. N. Ibrahim, Ahmed M. Khalaf, Doaa Mohamed El Demerdash, Marwa O. Elgendy, Haitham Saeed, Tamer M. Mahmoud, Heba F. Salem, Hoda Rabea   +9 more
doaj   +1 more source

Comparison of Splenectomy and Eltrombopag Treatment in the Second-Line Treatment of Immune Thrombocytopenic Purpura

Turkish Journal of Hematology, 2021
Objective: Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by isolated thrombocytopenia. While first-line treatments focus on inhibiting autoantibodies and platelet destruction, second- and third-line treatments ...
Mehmet Can Uğur, Sinem Namdaroğlu, Esma Evrim Doğan, Esra Turan Erkek, Nihan Nizam, Rafet Eren, Oktay Bilgir   +6 more
doaj   +1 more source